Pfizer announced today that study results across several
difficult-to-treat cancers will be presented at the 44th
American Society of Clinical Oncology (ASCO) annual meeting in Chicago
from May 30 to June 3, 2008. Pfizer will hold two briefings for
journalists on June 1 and investors on June 2.
Researchers will present the latest data from the breadth of Pfizer’s
oncology portfolio, focused in four areas of discovery:
anti-angiogenesis, signal transduction, immuno-oncology and
cytotoxics/potentiators.
Metastatic Renal Cell Carcinoma (mRCC)
-
Updated overall survival data from a Phase 3 trial evaluating
single-agent, oral SUTENT®
(sunitinib malate) versus interferon-alfa (IFN-α)
in the first-line treatment of mRCC will be presented in an oral
presentation by Dr. Robert Figlin, City of Hope on Saturday, May 31.
-
Phase 2 data evaluating the anti-tumor activity of axitinib in
patients with mRCC refractory to sunitinib and sorafenib, cytokines
and sorafenib, or sorafenib alone will be presented by Dr. Janice P.
Dutcher, New York Medical College on Saturday, May 31.
Non-small Cell Lung Cancer (NSCLC)
-
Phase 2 data evaluating the activity of the anti-IGF-1R antibody
CP-751,871 in combination with paclitaxel and carboplatin in NSCLC
will be presented by Dr. Daniel Karp, MD Anderson Cancer Center on
Monday, June 2.
-
Phase 1 clinical trial data exploring the safety and preliminary
activity of PF-299804, an irreversible pan-HER inhibitor will be
presented by Dr. Pasi A. Janne, Dana Farber Cancer Center on Monday,
June 2.
-
Characterization of NSCLC patients responding to anti-IGF-1R therapy
will be presented by Dr. Antonio Gualberto, Pfizer Global Research and
Development on Sunday, June 1.
Ewing’s Sarcoma
-
Results of the safety, pharmacokinetics and preliminary activity of
the anti-IGF-1R antibody CP-751,871 in sarcoma patients will be
presented by Dr. Paul Haluska, Mayo Clinic on Saturday, May 31.
Prostate Cancer (mHRPC)
-
Preliminary data from a Phase 2 study evaluating the safety and
tolerability of first-line SUTENT in combination with docetaxel and
prednisone in patients with metastatic hormone-refractory prostate
cancer will be presented by Dr. Daniel J. George, Duke University
Medical Center on Saturday, May 31.
Other Pfizer Data Presentations and Celldex
Data on the following compounds will also be presented at ASCO 2008:
Aromasin®
(exemestane), Camptosar®
(irinotecan HCl), CP-868596, PF-3512676, PF-562271 and tremelimumab.
Phase 2 data assessing the effect of EGFRvIII-targeted vaccine (CDX-110)
on immune response and time to progression when given with simultaneous
standard and continuous temozolomide in patients with Glioblastoma, a
form of brain cancer will be presented by Dr. John Sampson, Duke
University on Monday, June 2. Pfizer has signed an exclusive license
agreement with Celldex Therapeutics to develop and commercialize CDX-110.
About SUTENT®
(sunitinib malate)
SUTENT is an oral multi-kinase inhibitor approved for the treatment of
advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor
(GIST) after disease progression on or intolerance to imatinib mesylate.
SUTENT works by blocking multiple molecular targets implicated in the
growth, proliferation and spread of cancer. Two important sunitinib
malate targets, vascular endothelial growth factor receptor (VEGFR) and
platelet-derived growth factor receptor (PDGFR) are expressed by many
types of solid tumors, and are thought to play a crucial role in
angiogenesis, the process by which tumors acquire blood vessels, oxygen
and nutrients needed for growth. SUTENT also inhibits other targets
important to tumor growth, including KIT, FLT3 and RET.
Important SUTENT®
(sunitinib malate) Safety Information
Women of child bearing age who are (or become) pregnant during therapy
should be informed of the potential for fetal harm while on SUTENT.
Decreases in left ventricular ejection fraction (LVEF) to below the
lower limit of normal (LLN) have been observed. Patients with
concomitant cardiac conditions should be carefully monitored for
clinical signs and symptoms of congestive heart failure.
Patients should be monitored for hypertension and treated as needed with
standard antihypertensive therapy. CBCs with platelet count and serum
chemistries should be performed at the beginning of each treatment cycle
for patients receiving treatment with SUTENT.
The most common adverse reactions in mRCC and GIST clinical trials were
fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting,
dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot
syndrome, skin discoloration, altered taste, anorexia and bleeding.
For more information on SUTENT and Pfizer Oncology, including full
prescribing information for SUTENT (sunitinib malate), please visit www.pfizer.com.
